Pharmaceuticals, Biotechnology & Life Sciences

AbbVie’s Skyrizi® Canadian reimbursement and alliance boost pipeline value amid high‑PE scrutiny, offering investors long‑term growth and dividend stability.

Vaxart’s oral flu vaccine could revolutionize flu prevention, but the biotech’s shaky finances and regulatory hurdles keep investors wary.

Explore Hainan Haiyao’s week‑long trading swing—net Deep Stock Connect buying amid a falling free‑trade zone theme—and its drug pipeline’s upside potential.

BioCryst Pharmaceuticals pioneers oral, small‑molecule drugs for rare enzyme‑related diseases, balancing biotech volatility with a $1.49 billion market cap and a mission to transform unmet medical needs.

Innovation Pharmaceuticals Inc. develops small‑molecule therapies for inflammatory diseases, cancer, dermatology, and anti‑infectives—aiming to transform patient care.

ProText Mobility, Inc. pioneers highly‑absorbable botanical medicines, using plant extracts for better bioavailability and natural health solutions.

Lexaria Bioscience: Can its breakthrough API‑absorption tech beat a shaky stock? Dive into the company’s innovation, IP, and financial hurdles.

Evotec SE discloses voting‑rights filings, CEO’s marathon restructuring remarks, JPMorgan stake cut, and shares hit a 52‑week high—an in‑depth look at the company’s governance and market impact.

Verrica Pharmaceuticals, a clinical‑stage dermatology firm, is developing innovative treatments for skin diseases like molluscum contagiosum, navigating market volatility while pursuing breakthrough therapies.

Jiangsu Hengrui’s new CFDA approvals for six oncology and autoimmune drugs boost its pipeline depth and investor confidence, positioning the firm for Phase‑III success and higher earnings.